307. EFFICACY OF PRIMARY TREATMENT WITH IMMUNOGLOBULIN PLUS CYCLOSPORINE FOR PREVENTION OF CORONARY ARTERY ABNORMALITIES IN KAWASAKI DISEASE PATIENTS PREDICTED TO BE AT INCREASED RISK OF IVIG NON- RESPONSE (KAICA STUDY): A CONTROLLED, PHASE 3, RANDOMISED, OPEN-LABEL, BLINDED-ENDPOINTS TRIAL

Autor:	Takashi Soga, Ryota Ebata, Hiroshi Masuda, Kazunobu Ouchi, Masaaki Yanai, Yoshihiro Onouchi, Shunji Kurotobi, Yoshiaki Okuma, Yoshitomo Okajima, Nobuyuki Takada, Eiichi Yamamoto, Yuichi Nomura, Mamoru Ayusawa, Yuya Hashimura, Keiichi Hirono, Shinichi Takatsuki, Yukiko Ishiguchi, Mami Nakayashiro, Katsuki Hirai, Shigeto Fuse, Hiromichi Hamada, Junichi Sato, Tadashi Ariga, Masaru Terai, Hiroyuki Suzuki
Rok vydání:	2019
Předmět:	medicine.medical_specialty Randomization biology business.industry Surrogate endpoint medicine.disease medicine.anatomical_structure Increased risk Rheumatology Internal medicine medicine biology.protein Pharmacology (medical) Primary treatment Kawasaki disease Antibody Open label business Artery
Zdroj:	Rheumatology. 58
ISSN:	1462-0332 1462-0324
DOI:	10.1093/rheumatology/kez063.031
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e388f7f96c88cbbc0ceff5476ff86977 https://doi.org/10.1093/rheumatology/kez063.031 Zobrazit plný text záznamu